이노베이티브 인더스트리얼 프로퍼티스(IIPR) 2026년 3분기 실적 발표 콘퍼런스 콜: AFFO 성장 및 생명과학 분야 확장

핵심 요약

• 2026년 3분기 매출은 신규 임대 계약과 배틀 그린(Battle Green) 및 포프론트(4Front)로부터의 미납 임대료 회수에 힘입어 2분기 6,330만 달러에서 6,490만 달러로 증가했습니다.
• AFFO(조정운용자금)는 전분기 5,300만 달러(주당 1.83달러)에서 5,480만 달러(희석주당 1.96달러)로 전분기 대비 7% 증가했습니다. 임대료 회수는 경영진이 일회성 항목으로 설명한 건들을 포함해 주당 0.15달러의 기여를 했습니다.
• 이노베이티브 인더스트리얼 프로퍼티스(Innovative Industrial Properties)는 IQHQ 우선주 3,000만 달러와 엘와이프 파크(Alewife Park)에 대한 2억 4,500만 달러의 메자닌 대출을 포함해 생명과학 분야에 2억 7,500만 달러를 추가로 투자 약정했습니다.
• 총 생명과학 분야 약정액은 약 5억 4,500만 달러에 달했습니다. 경영진은 자금 집행이 완료되면 이러한 투자가 연간 수입의 약 26%를 차지할 것으로 전망하고 있습니다.
• 회사는 3분기 동안 6개 부동산에 대해 60만 4,000평방피트 규모의 신규 임대 계약을 체결했으며, 분기 종료 후 27만 평방피트 규모의 임대 계약을 추가로 완료했습니다. 연초 대비 누적 총 임대 활동은 12개 부동산에 걸쳐 약 130만 평방피트에 달했습니다.
• 분기 말 유동성은 1억 4,200만 달러였으며, 조정 EBITDA 대비 순부채 비율은 2.1배를 유지했고, 총 자산 대비 순부채 비율은 19%를 기록했습니다.

핵심 재무 데이터

사업 및 영업 실적

생명과학 분야 확장

이노베이티브 인더스트리얼 프로퍼티스는 이번 분기 동안 2억 7,500만 달러 규모의 신규 약정을 통해 생명과학 포트폴리오를 확장했습니다. 가장 큰 거래는 매사추세츠주 케임브리지에 위치한 27에이커 규모의 생명과학 캠퍼스인 엘와이프 파크(Alewife Park)에 대한 2억 4,500만 달러 규모의 메자닌 대출 약정이었습니다.

이 캠퍼스는 총 39만 2,000평방피트 규모의 기존 건물 3개동과 최대 36만 4,000평방피트를 추가로 개발할 수 있는 개발 부지 2곳을 포함합니다. 기존 건물의 78%는 라일라 사이언스(Lila Sciences)에 임대되었습니다.

IIPR은 거래 종결 시점에 약 1억 1,100만 달러를 집행했습니다. 남은 1억 3,400만 달러는 2027년 4분기까지 집행될 예정입니다. 경영진은 대출 기간 동안 이 대출이 평균 약 15.8%의 금리를 창출할 것으로 예상하고 있습니다.

IQHQ에 대한 기존 약정액 2억 7,000만 달러와 추가 3,000만 달러의 우선주 투자를 포함해 IIPR은 생명과학 분야에 총 약 5억 4,500만 달러를 약정했습니다. 경영진은 보스턴, 샌디에이고, 베이 에어리어 등에서 IQHQ 외의 추가 기회도 검토하고 있다고 밝혔습니다.

대마초 포트폴리오 임대

3분기는 회사 역사상 가장 활발한 임대 활동이 이루어진 분기였습니다. IIPR은 캘리포니아, 매사추세츠, 뉴욕, 오하이오, 워싱턴주에 있는 6개 부동산에 대해 60만 4,000평방피트 규모의 신규 임대 계약을 체결했습니다.

분기 종료 후 펜실베이니아에서 27만 평방피트 규모의 임대 계약이 추가로 완료되면서 7월 이후 총 임대 활동은 87만 4,000평방피트로 늘어났습니다. 연초 대비 누적 임대 활동은 12개 부동산에 걸쳐 약 130만 평방피트에 달해 전체 포트폴리오의 15%에 해당합니다.

회사는 또한 추가로 44만 6,000평방피트에 해당하는 계약을 진행 중이었습니다. 여기에는 콜로라도 소재 3개 부동산의 7만 2,000평방피트와 이전에 포프론트 벤처스(4Front Ventures)에 임대되었던 3개 부동산의 37만 4,000평방피트가 포함됩니다. 이러한 거래는 향후 실사, 라이선스 발급 및 규제 당국의 승인을 거쳐야 합니다.

자본 배치 및 유동성

분기 종료 후 IIPR은 9.25% 연이율의 시리즈 B 우선주 공모 발행을 완료하고 5,400만 달러의 총 공모 금액을 보고했습니다. 해당 자금은 엘와이프 파크 잔여 약정액의 일부 또는 전부를 집행하고 일반 기업 목적을 지원하는 데 사용될 예정입니다.

또한 회사는 8,750만 달러 규모의 회전한도 대출(리볼빙 크레디트) 만기를 90일 연장해 2027년 1월로 변경했습니다. 경영진은 생명과학 분야로의 다각화가 대출 기관의 관심을 높이고 자금 조달 기회를 확대했다고 말했습니다.

리스크 및 주시 사항

• 미납 임대료 회수는 3분기 실적에 주당 0.15달러의 기여를 했습니다. 경영진은 파마캔(PharmaCann), 패러렐(Parallel), 배틀 그린 관련 이익 중 일부는 일회성 항목이라고 지적했습니다.
• 실적 발표에서 언급된 임차인 5곳 중 4곳의 보증금이 모두 소진되었습니다. 더 캐나비스트 컴퍼니(The Cannabist Company)와 관련된 일부 부동산에는 보증금이 일부 남아 있습니다.
• 현재 공실은 80만 평방피트를 살짝 넘어서며, 이 중 약 3분의 2는 플로리다에 위치한 구 패러렐 소유 부동산 2곳에 집중되어 있습니다.
• 경영진은 신규 임차인 물색부터 임대 개시, 라이선스 이전, 규제 승인에 이르는 과정이 과거 경험상 6개월에서 18개월 소요되었다고 밝혔습니다.
• 추가 44만 6,000평방피트 규모의 임대 파이프라인은 조건부이며, 경영진은 이 협약들이 최종 임대 계약 체결로 이어질 것이라는 보장은 없다고 주의를 당부했습니다.
• 연방 차원의 대마초 재분류 시기와 결과는 여전히 불확실하며 추가적인 행정 검토가 필요합니다.

애널리스트 Q&A 주요 내용

• 재임대 일정: 경영진은 공실 상태인 대마초 부동산의 신규 임차인 유치에는 일반적으로 6개월에서 18개월이 걸린다고 설명했습니다. 플로리다 자산 2곳에 대해서는 여전히 자신감을 유지하고 있으며, 수수료, 임차인 환경 개선 비용 및 임대인 공사 비용을 포함한 연초 대비 재임대 비용은 평방피트당 10달러 미만이었습니다.
• 임대 모멘텀의 지속 가능성: 사상 최고치 수준의 실적은 동일 분기에 완료된 여러 거래와 사업 확장을 추진하는 운용사들의 관심 증가를 모두 반영한 결과입니다. 경영진은 플로리다 부동산을 주요 임대 중점 대상으로 꼽았습니다.
• AFFO 지속성: 경영진은 향후 가이던스를 제시하지 않았습니다. 경영진은 엘와이프 투자가 3분기 중 며칠간의 수입만 반영되었고 4분기에 더 큰 영향을 미칠 것으로 예상됨에도 불구하고, 3분기 실적에 일회성 임대료 회수금이 포함되어 있음을 강조했습니다.
• 추가 IQHQ 익스포저: IIPR은 다른 대출 기관으로부터 엘와이프 메자닌 대출에 대한 1억 5,500만 달러 규모의 추가 지분을 인수할 수도 있습니다. 경영진은 이용 가능한 자본과 해당 거래가 당시 최선의 자본 배치가 되는지 여부에 따라 결정될 것이라고 밝혔습니다.
• 생명과학 집중도: 이사회는 추가적인 고품질 IQHQ 기회에 대해 열린 태도를 유지하고 있으며, 경영진 또한 보다 광범위한 생명과학 산업 전반에 걸쳐 다각화를 추진할 의향이 있습니다.
• 우선주 자금 조달 유연성: 신규 시리즈 B 우선주는 시장가 발행(ATM) 프로그램을 통해 발행할 수 있어 또 다른 영구 자본 조달원 역할을 할 수 있습니다.

실적 발표 전화회의 전문

전체 실적 발표 컨퍼런스 콜 녹취록

경영진 발표

Operator

Hello, everyone. Thank you for joining us, and welcome to the Innovative Industrial Properties, Inc. Q3 2026 Earnings Call. [Operator Instructions]

I will now hand the conference over to Eli Kanter, Director of Finance.

Eli Kanter

Thank you for joining the call. Presenting today are Alan Gold, Executive Chairman; Paul Smithers, President and Chief Executive Officer; David Smith, Chief Financial Officer; and Ben Regin, Chief Investment Officer.

Before we begin, I'd like to remind everyone that some of the statements made during today's conference call, including statements regarding potential lease transactions that are subject of letters of intent, are forward-looking statements within the meaning of the safe harbor of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties. Actual results may differ materially, and we refer you to our SEC filings, specifically our most recent reports on Forms 10-K and 10-Q. For a full discussion of risk factors that could cause actual results to differ materially from those contained in the forward-looking statements, we are not obligated to update or revise any forward-looking statements, whether due to new information, future events or otherwise, except as required by law.

In addition, on today's call, we will discuss certain non-GAAP financial information such as FFO, normalized FFO, AFFO and adjusted EBITDA. You can find this information together with reconciliations to the most directly comparable GAAP financial measures, which is available on the Investor Relations section of our website at www.innovativeindustrialproperties.com, in our earnings release issued yesterday as well as in our 8-K filed with the SEC.

I'll now hand the call over to Alan.

Alan Gold

Thanks, Eli. Good morning, everyone, and thank you for joining our third quarter 2026 earnings call. The third quarter marked another period of significant execution for us, highlighted by the continued expansion of our life science investments, strong leasing activity across our existing portfolio, significant growth in our AFFO per share versus the second quarter and disciplined capital allocation.

Most notably, in September, we entered into a $245 million mezzanine loan commitment as a member of a lender syndicate to IQHQ for Alewife Park, a premier life science campus in Cambridge, Massachusetts, one of the country's leading life science markets. This highly accretive investment builds on our existing relationship with IQHQ and is expected to generate an average interest rate of approximately 15.8% over the term of the loan. Together with our original $270 million commitment to IQHQ and an additional $30 million investment through the preferred equity structure in September, we have now committed approximately $545 million to life sciences. Upon full funding, our life science investments are projected to account for approximately 26% of our total annualized income. We believe the current market environment continues to present compelling opportunities to deploy capital into the life science sector at attractive entry points. Our recent investments reflect both our confidence in the sector's long-term fundamentals and our disciplined approach to expanding our platform. At the same time, our team delivered strong leasing results across our cannabis portfolio. During the quarter, we executed new leases at 6 properties, totaling approximately 604,000 square feet, followed by an additional 270,000 square foot lease subsequent to quarter end. Together, these transactions represent approximately 874,000 square feet of gross leasing activity since the beginning of the third quarter, bringing our total gross leasing activity year-to-date to approximately 1.3 million square feet across 12 properties or 15% of our total portfolio.

Importantly, we continue to see strong interest across our portfolio, reinforcing our confidence in the underlying value of our real estate with an active pipeline of additional transactions. We remain focused on building upon this momentum, driving occupancy and positioning the portfolio for strong long-term performance. We delivered strong quarterly earnings as well with AFFO per share up 7% sequentially to $1.96 per share as we had continued recoveries of past due rents from certain tenants.

On the capital front and subsequent to quarter end, we completed a $54 million public offering of our 9.25% Series B preferred stock. We intend to use the net proceeds to fund all or a portion of our remaining commitment under our Alewife Park mezzanine loan commitment and for general corporate purposes. This transaction further demonstrates our ability to access the capital markets to fund attractive accretive investments and support the continued growth and diversification of our platform. Taken together, we believe these accomplishments underscore our strong management team and ability to deploy capital into accretive investments while actively managing and maximizing the value of our existing portfolio. We believe the combination of our growing life science investments, leasing momentum and financial flexibility positions us for future growth and long-term shareholder value creation.

With that, I'll turn the call over to Paul. Paul?

Paul Smithers

Thanks, Alan. At the federal level, cannabis reform continued to advance. Over the summer, the DEA completed its hearing on the proposed rescheduling of marijuana more broadly from Schedule I to Schedule III. While the proceedings remain subject to further administrative review and the timing and outcome of any final decision remains uncertain, we believe federal reform has the potential to provide meaningful benefits to operators, including improved economics and broader access to traditional sources of capital. We have also seen encouraging investment and M&A activity across the cannabis industry with established operators pursuing expansion in attractive markets, including Pennsylvania, Ohio, New York and Colorado. We believe this activity signals that well-capitalized operators remain committed to strategic growth and are actively investing in markets with strong long-term fundamentals. While financial challenges persist for certain operators, we continue to take decisive action across our portfolio. During the quarter, we regained possession of properties previously leased to Parallel, PharmaCann and The Cannabist Company. These transitions allow us to pursue leasing opportunities, strengthen our tenant base and improve overall portfolio performance.

Turning to the state level. Florida recently approved 22 additional vertically integrated medical cannabis licenses, representing a meaningful expansion of one of the country's largest medical cannabis markets. We believe the addition of new operators creates opportunities for further investment and expansion in the state, including demand for mission-critical real estate. More broadly, regulated cannabis markets continue to reach significant milestones. Massachusetts surpassed $10 billion in cumulative adult-use cannabis sales in September, while California has generated nearly $8.4 billion in cannabis tax revenue since 2018. These achievements underscore the scale and economic significance of established cannabis markets even as operators continue to navigate a challenging environment.

With that, I'll turn the call over to Ben to provide additional details on our portfolio activities.

Ben Regin

Thanks, Paul. Starting with our investment activity, we expanded our life science portfolio this quarter, closing on $275 million in new commitments. We invested an additional $30 million in IQHQ preferred equity and closed on a $245 million mezzanine loan commitment for Alewife Park, our premier life science campus in Cambridge, Massachusetts. Alewife Park is a 27-acre campus comprised of 3 existing buildings totaling 392,000 square feet and 2 pad-ready sites with up to 364,000 square feet of additional development potential. The existing buildings are 78% leased to Lila Sciences, an AI-enabled scientific discovery company. In addition to the approximately $800 million invested in the campus prior to our investment, we believe the quality of the real estate, established tenancy and location within one of the country's leading life science markets provide a strong foundation for accretive investment. Under the terms of our commitment, we funded approximately $111 million at closing, with the remaining $134 million expected to be funded through the fourth quarter of 2027. The loan is expected to generate an average interest rate of approximately 15.8% over the term. The financing will support the completion, tenant improvements, lease-up and stabilization of the campus. We believe the current environment continues to present attractive entry points in life science real estate, specifically for high-quality assets in the core life science markets of Boston, San Diego and the Bay Area. According to JLL, these 3 markets, along with Raleigh-Durham, have seen combined demand increased 44% year-over-year to nearly 8 million square feet in Q1 2026, driven by improved biotech funding conditions and biomanufacturing reshoring. Against this backdrop, we are actively growing our acquisition pipeline, seeing opportunities to invest in high-quality assets in these core markets at attractive risk-adjusted returns.

Turning to leasing. We had our most active quarter to-date with substantial activity across multiple properties and markets. During the third quarter, we executed new leases totaling 604,000 square feet across 6 properties located in California, Massachusetts, New York, Ohio and Washington. That momentum continued into the fourth quarter with an additional 270,000 square foot lease for a property located in Pennsylvania, bringing total leasing activity since July to 874,000 square feet. Beyond these completed transactions, we have a pipeline of additional transactions we believe are progressing toward execution. We have agreements in place covering 3 properties in Colorado, totaling 72,000 square feet, subject to the license transfer and regulatory approval process as well as agreements across 3 properties previously leased to 4Front Ventures totaling another 374,000 square feet. In total, these agreements cover an additional 446,000 square feet beyond the leases already executed. These agreements remain subject to customary due diligence, including licensing and regulatory approvals, and there can be no assurance that these discussions or negotiations will result in executed leases.

With that, I'll turn the call over to David.

David Smith

Thank you, Ben. For the third quarter, we generated total revenues of $64.9 million compared to $63.3 million in the second quarter. Our results benefited from new leases executed across our portfolio and recoveries of past due rents primarily from Battle Green and 4Front, which added $0.15 per share to our results this quarter as detailed in our press release yesterday.

Adjusted funds from operations, or AFFO, for the quarter totaled $54.8 million or $1.96 per diluted share compared to $53 million or $1.83 per diluted share in the prior quarter, driven by the previously mentioned items. We also continue to benefit from our investments in the life science sector. During the quarter, we recognized $10.4 million of interest and dividend income related to our financial investments in IQHQ, contributing to total interest and other income of $14.3 million for the quarter. Our third quarter results only had a few days of benefit from our recent Alewife investment, and we will have a larger beneficial impact on our fourth quarter results.

Turning to capital markets. Subsequent to quarter end, we priced an underwritten public offering of 2.2 million (sic) [ 2.0 million ] shares of our 9.25% Series B preferred stock at $25 per share, representing $54 million in gross proceeds of attractively priced perpetual capital. The proceeds from this offering are intended to support our previously announced mezzanine loan investment in the life science sector while providing additional flexibility to pursue future investment opportunities. We believe this transaction further demonstrates our ability to access multiple sources of capital to support the continued diversification and growth of our platform. Also subsequent to quarter end, we executed a 90-day extension of our existing $87.5 million revolving credit facility, extending its maturity till January of 2027. This extension provides us with additional flexibility to continue to evaluate our financing alternatives and manage our capital structure as we are seeing increased lender interest as a result of our continued diversification into the life science industry. Furthermore, as part of our diversification efforts, we are continuing to obtain increased research coverage and are pleased to welcome Stifel Nicolaus and Huntington Capital Markets to our equity research coverage, bringing the total number of firms covering IIP to 8. We appreciate the continued interest in our company and look forward to engaging with the broader investment community as we execute on our strategy.

Our balance sheet remains strong, supported by $142 million in total liquidity at quarter end, which does not include our recent $50 million preferred raise that further bolstered our total liquidity. We ended the quarter with net-debt-to-adjusted EBITDA of 2.1x, one of the lowest in the REIT industry and net-debt to total gross assets at a strong 19%. We continue to remain focused on maintaining a conservative capital structure and strong liquidity position while selectively pursuing attractive investment opportunities that support our long-term growth.

With that, operator, could you please open the call for questions?

Operator

[Operator Instructions] Your first question is from the line of Aaron Grey with Alliance Global Partners.

질의응답

Aaron Grey

So first question for me, just regarding some of the facilities that you've taken back possession of. I appreciate the color in terms of the timing for the 4Front properties. But as we think about some of the other properties, PharmaCann, Parallel and [ The Cannabist ] that you have possession of in August and September, how best to think about timing of when you can get those getting re-leased and rent revenue from those?

David Smith

Ben, do you want to take that?

Ben Regin

Yes. Aaron, no problem. Yes. I mean, I think historically, we've seen that can be anywhere from 6 to 18 months between sourcing a new tenant, lease commencement, license transfer, the regulatory process. I think we feel very good about our position and those assets in particular. Of the current vacancy, about 2/3 of that is our 2 Florida assets leased to Parallel or previously leased to Parallel. -- and the Florida market has been performing very well this year. They set a new sales record in July, and we really like where that market is going and feel that those assets are well positioned for future leasing activity as well as, again, we'd like to highlight the capital-efficient nature in which we've been able to retenant these assets. For year-to-date, you're well below $10 a foot, all in for commissions, TIs, landlord work, really everything to retenant these assets.

Aaron Grey

Okay. Great. I appreciate that color. Second question for me. I know last quarter, we talked about diversification split between cannabis and life sciences. But wanted to dive more now in terms of diversification within the life sciences sector specifically and how you think about further opportunities within life sciences and having some diversification versus concentration with existing IQHQ and affiliates?

Alan Gold

Yes. I mean I think that we -- as we started the process of diversification, we've, I think, executed well. We've focused our efforts to date with investments into IQHQ, which we think are investments that are well secured by the positions in which we are in at IQHQ. We believe that, that has given us a very good window into what's going on in the life science industry. And we believe that our diversification will continue and that there are unique opportunities, not only within IQHQ, but within the broader life science industry that we are certainly exploring and look forward to exploring those opportunities in the future.

Operator

Your next question is from the line of Bill Kirk with ROTH Capital Partners.

William Kirk

I guess to start, there's still -- there's a chunk of AFFO that's still coming from defaulted properties, whether it's security deposits or payments that are continuing. So I guess the simple question is, would you expect quarterly AFFO to remain above that $1.90 payout?

Alan Gold

David, why don't you take that?

David Smith

Yes. I think, Bill, as you know, obviously, we had a very strong quarter. I mean AFFO was up 7% sequentially, drove our payout ratio down to 97% for this quarter. So very happy with our results there. In terms of the go forward, obviously, we don't give guidance. I think we have done a, a great job historically of recovering these past due rent payments that are owed to us. And again, that benefited this quarter. I think as you're noting, there were a number of benefits this quarter as we detailed in our press release that will be nonrecurring, including PharmaCann, Parallel and Battle Green benefit as well.

William Kirk

And maybe that segues into a follow-up there. For the Battle Green, there was a change in control there, right, with Vireo. So what should we expect from that one going forward? We can see the payments in the third quarter. But what do those payments maybe look like going forward from those assets?

Ben Regin

Bill, it's Ben. Yes, I mean, we typically don't disclose lease terms on new leases. I mean we really viewed that as we had a defaulted tenant and we were very aggressive in enforcing our rights under the lease and received interest from a new group that wanted to execute a lease for that asset before we were even able to wrap up that legal process. So I thought that was -- really spoke to the quality of the real estate and getting another tenant in there so quickly, and we're very pleased to have Vireo in there and up and running.

William Kirk

I'm going to sneak one last one in. Could you give us a little more detail on the -- I think it was 16 terminated leases. It looks to me like a mix of retail and cultivation. So I guess what type of properties were they? Was it concentrated to a particular tenant or a particular market? And then I'll pass it along.

Ben Regin

Yes. No problem. Yes. So of those, vast majority from a square footage perspective is going to be the cultivation assets. Almost half of that is the 2 Florida assets that we recovered from Parallel. You also had a couple from PharmaCann as well as Battle Green and 4Front. I think it's also important to note that there's a number of those that we already have new leases executed. So that Battle Green example we just talked about, there was a lease that we signed in New York that was the termination of getting PharmaCann out and bringing a new tenant in there. And then the 4Front asset in Washington, where, again, we have a new tenant in there up and running and paying rent already. So again, very pleased with the execution on those.

Operator

Your next question is from the line of Tom Catherwood with BTIG.

William Catherwood

Maybe circling back on Aaron's leasing question. Your Q3 leasing activity was a record. Was the increase more a result of deals that you've been working on for a long time, all reaching a conclusion at once? Or has customer activity accelerated? And if it's the latter, kind of what's driving the change? And how sustainable do you think that demand is?

Ben Regin

Yes. Tom, it's Ben. I think it's a combination of those. I mean real estate transactions are obviously chunky in nature. So we had a number of those all come together in the same quarter. I think we are still pleased with the velocity we've seen in the re-tenanting. And I think that there's some optimism and some increased M&A activity that we've seen and the groups that are out there that are getting back on offense in some of these states where they want to expand and they see the value in the real estate that we have. Going forward, the remaining vacancy currently is a little over 800,000 square feet, and the vast -- 2/3 of that is our 2 Parallel assets in Florida. So that will be our focus. Like we mentioned before, we feel very good about the Florida market setting a new monthly sales record here in July and 20% year-over-year increase in sales in the Florida market. They just issued some new licenses. We feel we're very well positioned with those 2 assets.

William Catherwood

Great. Appreciate that, Ben. And then maybe last one for me, going over to the IQHQ investment and kind of thinking specifically about the preferreds. When you first looked at the original investment with IQHQ and the milestones that would have been associated with the Series G funding, the draws the company would have made, how has the performance compared to your initial underwriting or expectations? And is the incremental $30 million that you put in this quarter tied to better execution or higher costs?

Alan Gold

So I think the -- as we described in the prepared remarks, the life science industry continues to improve. And that -- so that -- and I think IQHQ is benefiting from that increase, including having a stronger -- having more leasing activity, particularly at Alewife, getting it up to 78% and perhaps additional demand there emerging. So we see -- and we see their success in their Redwood City Elco Yards property and even some new leasing activity emerging in the San Diego market. So we're -- they are performing. That's number one. And number two is the additional capital investment was an opportunity that we had that we took advantage of. They had good news, capital needs, and we had capital available that we believe was very well priced and very accretive to IIPR.

Operator

Your next question is from the line of Rob Stevenson with Huntington.

Robert Stevenson

David, I guess to ask the revenue question a little differently. Are there any additional security deposits beyond the $3.8 million you did in the third quarter that you could pull down in the fourth quarter for those tenants that are currently not paying or where the lease is in transition, but not yet commenced, et cetera? Or are you tapped out of the security deposits for those tenants that you listed in the earnings release at this point?

David Smith

Yes, sure. Rob, 4 of the 5 tenants, those are all fully exhausted. We do still have a handful of properties with the cannabis company where we do still have some security deposits on hand.

Robert Stevenson

Okay. That's helpful. And then, Alan, how should we be thinking about the likelihood that you'll acquire the incremental $155 million of the IQHQ mezz loan and sort of what dictates that in your mind?

Alan Gold

Well, not acquire. They will draw on that additional $155 million as they continue to build out the improvements in the -- for the Lila lease. And so we believe that, that will get drawn over time, barring any changes.

Robert Stevenson

So that's in addition to the $134 million that's yet to be drawn? So it's actually $289 million of incremental draw for you guys on that, right? Because it was $245 million with $111 million at closing, and there was $134 million left on that $245 million, and then you had the option to acquire the $155 million from another lender on the same terms.

Alan Gold

I see. I see. I'm sorry, I didn't understand that. Okay. Go ahead. All right. So the opportunity for us to acquire that additional, I think that that's a possibility. It's part of our agreement. It's what we are looking to do. We have to have the available capital available to us to be able to make that determination. And if we determine that, that's the best allocation of capital when that opportunity surfaces, we will certainly look at that. It would be a very accretive transaction should it occur.

Robert Stevenson

Okay. And then I guess just the last one to sort of follow up on that. How is the Board thinking about sort of [ max ] investment in IQHQ at this point as that continues to ratchet up? I mean, are you getting to the point where if you did pull down that extra $155 million that, that would be it? Or is there still the Board thinking that there's still room for incremental investment there?

Alan Gold

I mean if you think about the opportunity, we believe the assets that IQHQ has are of high quality, which is why we made an additional investment in the Alewife transaction. That is just one example of a very high-quality asset that has a tremendous amount of leasing already in place and additional leasing activity. So if there are other opportunities, I think the Board would look, certainly would consider it. We don't think that the -- that our investments are really just investments in IQHQ, but tangentially also investments in the life science industry and are a vehicle for us to diversify from our portfolio, from just the cannabis focus that we had. This diversification that we are doing has increased our access to new lenders and new capital sources. So it's proven to be what the Board had thought it would be, which is a very good move for the company and to give us greater access to capital. And I think that will probably -- if there are other opportunities, we will probably continue to do that given that our diversification desire is higher than where we are sitting right today.

Robert Stevenson

Okay. And then -- I lied, one last one, David. With the new preferred issuance, do you have the opportunity to open that up via an ATM and issue incrementally there? Or is that needed to come back if you wanted to issue additional on that series that you have to do a fully marketed offering?

David Smith

No, we do have the ability to do the ATM on that new Series B. So I think as you're alluding to, we had that capability in our Series A. We had very strong demand and success of raising perpetual capital for that Series A this year. And as you know, the Series B has that ability as well.

Operator

There are no further questions at this time. I will now turn the call back to Alan Gold for closing remarks.

Alan Gold

Thank you. And first of all, I'd like to thank all of those who have joined on the call today and for the very good questions. I'd like to thank our team for their very hard work in this past quarter. And we certainly look forward to the opportunities for IIPR in the future. With that, thank you all, and we'll end the call.

Operator

This concludes today's call. Thank you for attending. You may now disconnect.